FDA Approves Landmark Pancreatic Cancer Pill That Nearly Doubled Survival
FDA Approves Landmark Pancreatic Cancer Pill That Nearly Doubled Survival/ TezzBuzz/ WASHINGTON/ J. Mansour/ The FDA granted expedited approval to daraxonrasib, the first-of-its-kind pill targeting mutated proteins that fuel most pancreatic cancers. In a 500-patient study, people receiving the drug had a median survival of 13.2 months, compared with 6.7 months for those receiving additional … Read more